Last reviewed · How we verify

Topical Lidocaine 4% Cream

Children's Hospital of Philadelphia · FDA-approved active Small molecule

Topical Lidocaine 4% Cream is a Local anesthetic Small molecule drug developed by Children's Hospital of Philadelphia. It is currently FDA-approved for Topical anesthesia for minor procedures and pain relief in pediatric patients, Local anesthesia for needle procedures and wound care. Also known as: AneCream™; Anestacon®; Dalcaine®; L-M-X™4; Xylocaine®.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Topical anesthesia for minor procedures and pain relief in pediatric patients, Local anesthesia for needle procedures and wound care.

At a glance

Generic nameTopical Lidocaine 4% Cream
Also known asAneCream™; Anestacon®; Dalcaine®; L-M-X™4; Xylocaine®
SponsorChildren's Hospital of Philadelphia
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby blocking the generation and conduction of action potentials. When applied topically as a 4% cream, it penetrates the skin to anesthetize superficial nerves and tissues. This reversible blockade of nerve conduction results in loss of sensation in the treated area.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical Lidocaine 4% Cream

What is Topical Lidocaine 4% Cream?

Topical Lidocaine 4% Cream is a Local anesthetic drug developed by Children's Hospital of Philadelphia, indicated for Topical anesthesia for minor procedures and pain relief in pediatric patients, Local anesthesia for needle procedures and wound care.

How does Topical Lidocaine 4% Cream work?

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

What is Topical Lidocaine 4% Cream used for?

Topical Lidocaine 4% Cream is indicated for Topical anesthesia for minor procedures and pain relief in pediatric patients, Local anesthesia for needle procedures and wound care.

Who makes Topical Lidocaine 4% Cream?

Topical Lidocaine 4% Cream is developed and marketed by Children's Hospital of Philadelphia (see full Children's Hospital of Philadelphia pipeline at /company/children-s-hospital-of-philadelphia).

Is Topical Lidocaine 4% Cream also known as anything else?

Topical Lidocaine 4% Cream is also known as AneCream™; Anestacon®; Dalcaine®; L-M-X™4; Xylocaine®.

What drug class is Topical Lidocaine 4% Cream in?

Topical Lidocaine 4% Cream belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Topical Lidocaine 4% Cream in?

Topical Lidocaine 4% Cream is FDA-approved (marketed).

What are the side effects of Topical Lidocaine 4% Cream?

Common side effects of Topical Lidocaine 4% Cream include Skin irritation or erythema at application site, Allergic contact dermatitis, Systemic toxicity (rare with topical use).

What does Topical Lidocaine 4% Cream target?

Topical Lidocaine 4% Cream targets Voltage-gated sodium channels and is a Local anesthetic.

Related